NASDAQ:PRME Prime Medicine Q3 2025 Earnings Report $2.96 +0.08 (+2.60%) As of 11:14 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Prime Medicine EPS ResultsActual EPS-$0.32Consensus EPS -$0.28Beat/MissMissed by -$0.04One Year Ago EPSN/APrime Medicine Revenue ResultsActual Revenue$1.23 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APrime Medicine Announcement DetailsQuarterQ3 2025Date11/7/2025TimeBefore Market OpensConference Call DateFriday, November 7, 2025Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Prime Medicine Earnings HeadlinesPrime Medicine (NASDAQ:PRME) Earns Buy Rating from Chardan CapitalSeptember 27 at 1:36 AM | americanbankingnews.comPrime Medicine Clears FDA Hurdle For Gene-Editing Therapy Targeting Rare Genetic Disease; Stock UpSeptember 26 at 2:36 PM | rttnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.September 29 at 1:00 AM | Banyan Hill Publishing (Ad)Prime Medicine's PM647 Clears Key Regulatory Hurdle, Oppenheimer SaysSeptember 26 at 3:40 AM | finance.yahoo.comPrime: A Buy Due To BLA Filing H1 '27 And Continued PM647 AdvancementSeptember 25, 2026 | seekingalpha.comPrime Medicine, Inc.: Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin DeficiencySeptember 25, 2026 | finanznachrichten.deSee More Prime Medicine Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prime Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prime Medicine and other key companies, straight to your email. Email Address About Prime MedicinePrime Medicine (NASDAQ:PRME) is a biotechnology company developing genetic medicines using its proprietary Prime Editing platform. The company’s technology is designed to make precise changes to DNA, including the insertion, deletion, or replacement of genetic sequences, with the goal of addressing disease-causing mutations. Prime Medicine is focused on developing treatments for genetic diseases and other serious conditions. Its research programs use Prime Editing in approaches that may modify a patient’s own cells, including ex vivo cell-editing applications in which cells are edited outside the body and then returned to the patient. The company’s development pipeline has included programs for inherited disorders such as chronic granulomatous disease, as well as potential applications in immunology, oncology, and other therapeutic areas. Founded in 2019, Prime Medicine is headquartered in Cambridge, Massachusetts. The company was established around Prime Editing technology developed by researchers including David R. Liu, a professor at Harvard University and the Broad Institute of MIT and Harvard. Prime Medicine’s activities are primarily centered on research, clinical development, and potential commercialization of gene-editing therapies.View Prime Medicine ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
